Wegovy Pill Sales Beat Forecasts, Novo Lifts Outlook

Wegovy pill sales just gave Novo Nordisk the plot twist it badly needed. The Danish drugmaker reported third-quarter numbers on Wednesday that beat forecasts, and it raised its full-year outlook for the third time this year, according to CNBC.

The numbers behind the Wegovy pill sales

The pill, which launched in the United States in January, brought in about five point four billion Danish crowns, roughly eight hundred ten million dollars, according to Reuters. That is up fifty-three percent from the second quarter and clear of the four point six billion crowns analysts had pencilled in.

Reuters reports the United States made up four point one eight billion crowns of that total, with international markets adding one point two two billion. Novo also said U.S. prescriptions hit about three point six million in the quarter, and more than eight million since launch.

Zoom out and the whole company beat the Street. Total third-quarter sales landed at seventy-nine point two billion crowns, about eleven point nine billion dollars, up four percent at constant exchange rates, against a FactSet estimate of seventy-three point six billion.

A guidance raise, again

Novo now expects adjusted sales and operating profit growth between negative two percent and positive two percent at constant exchange rates. It previously guided to a drop of up to six percent, as CNBC notes, so the new range is a real upgrade.

The company credits higher GLP-1 volumes in both the U.S. and abroad. It also expects the pill to be available in more than twenty markets by the first half of next year, ahead of its earlier target, helped by strong manufacturing output and faster regulatory approvals.

Shares jumped as much as six percent in early trading. Even so, they are still down about thirteen percent for the year, so this is a bounce, not a victory lap.

Why the Lilly rivalry matters

For the past couple of years Novo has been the underdog. Eli Lilly caught up and then passed it in the huge U.S. market, and Novo spent that stretch issuing profit warnings and reshuffling leadership.

The pill is the main route back. CNBC reports that CEO Mike Doustdar says Novo still holds about eighty percent market share in the segment, even with competition strengthening. Lilly's rival pill, Foundayo, missed analyst expectations last quarter, although Lilly says new patients doubled.

The pill is still only about six percent of expected Novo sales, per Reuters, so the injectable Wegovy and Ozempic franchises still carry the company. Both also beat expectations this quarter.

Why this matters outside Wall Street

Weight-loss drugs are no longer a niche story. CNBC notes that GLP-1 medicines are now used by around ten percent of Americans, which is why a pill version, easier to take than a weekly injection, gets so much attention from investors and patients alike.

Prices are part of that conversation too. A health news digest reports that Novo lists U.S. self-pay prices for the pill at between one hundred forty-nine and two hundred ninety-nine dollars a month, while the list price is set to rise to six hundred seventy-five dollars from January first. Those are sales and pricing figures, not health outcomes, so they say nothing yet about how well the pill works for any one person.

Novo also took an impairment charge of eight point seven billion crowns this quarter, tied to a heart drug candidate and a trim of its manufacturing network, which pulled reported operating profit down even as adjusted profit rose twenty-seven percent. That gap is worth remembering before calling the comeback complete. Keep an eye on the world section for more business moves like this one.

What to watch next

Do not expect the story to be all upside. Analysts at Citi kept a neutral rating, pointing to uncertainty over weight-loss drug pricing and the lack of a clear Wegovy successor. The outlook also assumes a sales decline in the U.S.

Novo also announced that finance chief Karsten Munk Knudsen is leaving at the end of the year after twenty-seven years, with Luigi La Corte of Galderma set to take over.

Doustdar was careful about the hype. "Turnaround and recovery is not done based on one data point, on one quarterly good result," he said. For anyone tracking the GLP-1 boom, the next few quarters will show whether the pill keeps climbing. More in health coverage here.